Acetazolamide (All indications) - Medication and Pregnancy KB

Acetazolamide (All indications)

Exposed non-exposed, cohort studies

Study	Country Study period Study design	Data source	Exposure definition	Non-exposure definition	Exposition period	Sample size (exposed/unexposed) Or (case / control)	Remarks	Risk of bias
Battino (Acetazolamide) (Epilepsy) 2024	Worldwide (47 countries) 1999 - 2022 prospective cohort	The International Registry of Antiepileptic Drugs and Pregnancy (EURAP).	Pregnant women with epilepsy exposed to Acetazolamide monotherapy at the time of conception.	exposed to other treatment, sick Pregnant women with epilepsy exposed to lamotrigine monotherapy at the time of conception.	early pregnancy	2 / 3584	Overlapping/Update: Malfo as a whole: Battino 2024 (1999-2022) updates and totally includes Tomson 2018 (1999-2016), Tomson 2011 and Jimenez 2020 (1 center in Spain 2000-2018) => Use of Battino 2024 for the 8 (plus 16 in eSupp) monotherapies studied.
Battino (Acetazolamide) (Epilepsy) 2024	Worldwide (47 countries) 1999 - 2022 prospective cohort		Reporting physicians collected information on drug therapy after each trimester.		early pregnancy	2 / 3584
Christensen (Acetazolamide) (All indications) (Controls exposed to LTG) 2024	Denmark, Finland, Iceland, Norway, and Sweden 1996 - 2017 population based cohort retrospective	Nordic population-based cohort study including register data from Denmark, Finland, Iceland, Norway, and Sweden–the SCAN-AED project.	Children of mothers who had redeemed at least one prescription of Acetazolamide monotherapy from 30 days before the first day of the last menstrual period to the date of birth (i.e., the exposure period).	exposed to other treatment, sick Children of mothers who had redeemed at least one prescription of Lamotrigine monotherapy from 30 days before the first day of the last menstrual period to the date of birth (i.e., the exposure period).	during pregnancy (anytime or not specified)	127 / 8756	Denmark (1997–2017), Finland (1996–2016), Iceland (2004–2017), Norway (2005–2017), and Sweden (2006–2017).
			Prenatal exposure was identified via national prescription registers. These registers contain the Anatomical Therapeutic Chemical (ATC) classification code (www.whocc.no) and the date of dispensing.		during pregnancy (anytime or not specified)	127 / 8756
Christensen (Acetazolamide) (All indications) (Controls unexposed, general population) 2024	Denmark, Finland, Iceland, Norway, and Sweden 1996 - 2017 population based cohort retrospective	Nordic population-based cohort study including register data from Denmark, Finland, Iceland, Norway, and Sweden–the SCAN-AED project.	Children of mothers who had redeemed at least one prescription of Acetazolamide monotherapy from 30 days before the first day of the last menstrual period to the date of birth (i.e., the exposure period).	unexposed (general population or NOS) Children of mothers who had not redeemed prescription of anti-seizure medication.	during pregnancy (anytime or not specified)	127 / 4467848	Denmark (1997–2017), Finland (1996–2016), Iceland (2004–2017), Norway (2005–2017), and Sweden (2006–2017).
			Prenatal exposure was identified via national prescription registers. These registers contain the Anatomical Therapeutic Chemical (ATC) classification code (www.whocc.no) and the date of dispensing.		during pregnancy (anytime or not specified)	127 / 4467848
Samrén (Acetazolamide) 1999	Netherlands 1972 - 1994 retrospective cohort	28 hospitals in four provinces of the Netherlands and National Perinatal Data Base LVR.	Children born to mothers with epilepsy and using acetazolamide monotherapy at least during the first trimester of pregnancy	unexposed, disease free Children born to nonepileptic nonexposed women.	at least 1st trimester	1 / 2000
Samrén (Acetazolamide) 1999	Netherlands 1972 - 1994 retrospective cohort		Data were collected from medical records and include medication. The prescribed dose of thedrugs was also retrieved from obstetric files.		at least 1st trimester	1 / 2000
Vajda (Acetazolamide) (Controls exposed to Lamotrigine, sick) 2019	Australia 1999 - 2018 prospective cohort	The Australian Register of Antiepileptic Drugs in Pregnancy.	Offsprings born from women nearly always with epilepsy exposed to acetazolamide in monotherapy in at least the first trimester of pregnancy. (This is a subgroup of exposure among the whole exposed group considered in the study).	exposed to other treatment, sick Offsprings born from women nearly always with epilepsy exposed to lamotrigine in monotherapy in at least the first trimester of pregnancy.	at least 1st trimester	1 / 406	Women with epilepsy accounted for 98.3%. Study design partly completed with Vajda 2013. Jazayeri 2018 malformations results are completely overlap by Vajda 2019.
	Australia 1999 - 2018 prospective cohort		Details are obtained by four in-depth telephone interviews with the women. Details provided by the participants are confirmed, as far as possible, by the treating medical practitioners and through hospital records.		at least 1st trimester	1 / 406
Vajda (Acetazolamide) (Controls unexposed, sick) 2019	Australia 1999 - 2018 prospective cohort	The Australian Register of Antiepileptic Drugs in Pregnancy.	Offsprings born from women nearly always with epilepsy exposed to acetazolamide in monotherapy in at least the first trimester of pregnancy. (This is a subgroup of exposure among the whole exposed group considered in the study).	unexposed, sick Offsprings born from women nearly always with epilepsy not treated with antiepileptic drugs in at least the first half of pregnancy.	at least 1st trimester	1 / 176	Women with epilepsy accounted for 98.3%. Study design partly completed with Vajda 2013. Jazayeri 2018 malformations results are completely overlap by Vajda 2019.
Vajda (Acetazolamide) (Controls unexposed, sick) 2019	Australia 1999 - 2018 prospective cohort		Details are obtained by four in-depth telephone interviews with the women. Details provided by the participants are confirmed, as far as possible, by the treating medical practitioners and through hospital records.		at least 1st trimester	1 / 176

Case-control studies

Study	Country Study period Study design	Data source	Case	Control	Exposition	Exposition period	Sample size (exposed/unexposed) Or (case / control)	Remarks	Risk of bias

Risk of bias: : NA; : low; : moderate; : serious; : critical; : unclear;

Empty. There are no case-control studies available for this drug.

master protocol